Spinal injection of immunotherapy shows promise for hard-to-treat brain metastasis
NCT ID NCT05598853
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 23 times
Summary
This early-phase study tests whether injecting two immunotherapy drugs directly into the spinal fluid, along with standard IV doses, is safe and can shrink tumors in the brain and spinal cord lining. It includes 26 adults with advanced lung cancer or melanoma that has spread to these areas. The goal is to find the best dose and see if this approach helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Basel
Basel, Switzerland
-
University Hospital Geneva
Geneva, Switzerland
-
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland
Conditions
Explore the condition pages connected to this study.